Key Points Reexpansion of CAR T cells led to further investigations which confirmed the clonal nature of this expansion.doi:10.1182/bloodadvances.2019000219Nirali N. Shah *Haiying Qin *Bonnie YatesLing SuHaneen ShalabiMark RaffeldMark A. Ahlman...
Based on the performance of CD22-CAR T cells in vitro, we selected CD22MN-CAR T cells for animal experiments, as outlined in Fig. 5A. We injected mice with 1 × 106 Raji-Luciferase cells (Fig. 5B) through the tail vein and then infused 5 × 106 untreated T cells or CD22MN-CAR ...
Despite the proven effectiveness of CAR T cells targeting CD19 and CD22 in hematological malignancies, it is imperative to note that their production remains a highly complex process. Unlike T cells, NK cells eliminate targets in a non-antigen-specific manner while avoiding graft vs. host ...
Relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a challenging disease with low rates of remission and survival in adult patients. Anti-CD19 Chimeric Antigen Receptor T-cells (CAR-Ts) therapies have been approved for these patients. Dual-target CAR-Ts against CD19 and ...
In vitro tumor-cytotoxicity effect of CART 19 and CART 22 cells at effector/target ratios of 25:1, 5:1 and 1:1. Levels of IL-6 after CAR T cell therapy. Levels of ferritin after CAR T cell therapy. Dynamic white blood cell numbers and lymphocyte numbers before and afterCAR T cell ...
doi:10.1097/01.HS9.0000563232.87511.d2Li, J.Ho, J.Ma, F.Li, Y.Huang, C.Liu, L.HemaSphere
doi:10.1097/01.HS9.0000563232.87511.d2Li, J.Ho, J.Ma, F.Li, Y.Huang, C.Liu, L.HemaSphere
All pts received conditioning regimen of fludarabine and cyclophosphamide intravenously for 3 consecutive days with doses of 30 mg/m2/day and 250 mg/m2/day, respectively before a single infusion of CAR-T cells. The level of infused CAR-T cell proliferation in PB was analyzed by qPCR and ...